<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="126036">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01874574</url>
  </required_header>
  <id_info>
    <org_study_id>OrthoTU-01</org_study_id>
    <nct_id>NCT01874574</nct_id>
  </id_info>
  <brief_title>Intra-articular Corticosteroid Injection Compared With Single-Shot Hyaluronic Acid for Treatment of Osteoarthritis Knee</brief_title>
  <official_title>Intra-articular Corticosteroid Injection Compared With Single-Shot Hyaluronic Acid for Treatment of Osteoarthritis Knee: A Prospective, Double-blind Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Thammasat University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Thammasat University</source>
  <oversight_info>
    <authority>Thailand: Ethical Committee</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Corticosteroid and Hylan G-F 20 are both effective in improving pain and function of
      osteoarthritic knee patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Corticosteroid and Hylan G-F 20 are both effective in improving pain and function of
      osteoarthritic knee patients up to 6 months.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2011</start_date>
  <completion_date type="Actual">September 2013</completion_date>
  <primary_completion_date type="Actual">June 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>WOMAC Score</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Change from Baseline in WOMAC score at 6 months</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Visual Analogue Scale(VAS)</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Change from Baseline in VAS score at 6 months</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">100</enrollment>
  <condition>Knee Osteoarthritis</condition>
  <arm_group>
    <arm_group_label>Single shot Hylan G-F 20 (Synvisc)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intra-articular injection of the Single shot 6 mL of Hylan G-F 20 (Synvisc)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Corticosteroid (Triamcinolone acetonide)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intra-articular injection of 1 mL of 40 mg Triamcinolone acetonide plus 5 mL of 1% xylocaine with adrenaline injected at the knee by single shot</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hylan G-F 20</intervention_name>
    <description>After full aseptic preparation, Single shot intra-articular injection either 6 mL of Hylan G-F 20 or 1 mL of 40 mg triamcinolone acetonide plus 5 mL of 1% xylocaine with adrenaline were injected into the joint cavity using the infero-lateral approach via a 21-gauge needle.</description>
    <arm_group_label>Single shot Hylan G-F 20 (Synvisc)</arm_group_label>
    <other_name>Synvisc</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Corticosteroid</intervention_name>
    <description>After full aseptic preparation, Single shot intra-articular injection either 6 mL of Hylan G-F 20 or 1 mL of 40 mg triamcinolone acetonide plus 5 mL of 1% xylocaine with adrenaline were injected into the joint cavity using the infero-lateral approach via a 21-gauge needle.</description>
    <arm_group_label>Corticosteroid (Triamcinolone acetonide)</arm_group_label>
    <other_name>Triamcinolone acetonide</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Clinical diagnosis of knee OA

          -  Knee pain for most days of the prior month

          -  Radiographic evidence consistent with knee OA

          -  Aged between 40 and 80 years old

        Exclusion Criteria:

          -  Lumbar spondylosis

          -  Gross deformity of the knee

          -  Co-existent inflammatory or crystal arthritis

          -  Prior knee surgery

          -  Injury to the knee in the preceding 6 months

          -  Any intra-articular injection in the preceding 3 months

          -  Pregnant or Lactating

          -  Current infection in the affected knee

          -  Inability to provide informed consent
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nattapol Tammachote, MD, MSc</last_name>
    <role>Study Director</role>
    <affiliation>Department of Orthopaedics, Thammasat University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Thammasat University Hospital, Thammasat University</name>
      <address>
        <city>Prathumthani</city>
        <zip>12121</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Thailand</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 21, 2014</lastchanged_date>
  <firstreceived_date>September 5, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Thammasat University</investigator_affiliation>
    <investigator_full_name>Phonthakorn Panichkul</investigator_full_name>
    <investigator_title>Dr. Phonthakorn Panichkul</investigator_title>
  </responsible_party>
  <keyword>Knee Osteoarthritis</keyword>
  <keyword>Corticosteroid</keyword>
  <keyword>Hyaluronic acid</keyword>
  <keyword>Intra-articular injection</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Osteoarthritis, Knee</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hyaluronic Acid</mesh_term>
    <mesh_term>Triamcinolone Acetonide</mesh_term>
    <mesh_term>Triamcinolone hexacetonide</mesh_term>
    <mesh_term>Triamcinolone</mesh_term>
    <mesh_term>Triamcinolone diacetate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
